NASDAQ:PRNBPrincipia Biopharma Stock Price, Forecast & News

$66.91

-0.97 (-1.43 %)

(As of 05/28/2020 01:49 PM ET)

Add

Compare

Today's Range

$66.03

Now: $66.91▼

$69.30

50-Day Range

$57.42

MA: $62.94▼

$69.00

52-Week Range

$25.35

Now: $66.91▼

$75.65

Volume56,279 shs

Average Volume239,164 shs

Market Capitalization$2.21 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.66

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.

Beat the Market (BTM) Rank^™

2.5 Analyst's Opinion

Consensus Rating
Principia Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $78.60, Principia Biopharma has a potential upside of 17.5% from its current price of $66.91.
Amount of Analyst Coverage
Principia Biopharma has only been the subject of 4 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Principia Biopharma has received 87 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Principia Biopharma has received 92 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Principia Biopharma has received 51.40% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Principia Biopharma and other stocks. Vote “Outperform” if you believe PRNB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRNB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Principia Biopharma does not currently pay a dividend.
Dividend Growth
Principia Biopharma does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Principia Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,251,319.00 in company stock.
Percentage Held by Insiders
Only 28.98% of the stock of Principia Biopharma is held by insiders.
Percentage Held by Institutions
92.44% of the stock of Principia Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Principia Biopharma are expected to decrease in the coming year, from ($3.62) to ($4.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Principia Biopharma is -27.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Principia Biopharma is -27.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Principia Biopharma has a P/B Ratio of 6.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.18 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PRNB

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.principiabio.com

Phone650-416-7700

Debt

Debt-to-Equity RatioN/A

Current Ratio17.54

Quick Ratio17.54

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$35.16 million

Price / Sales62.88

Cash FlowN/A

Price / Cash FlowN/A

Book Value$10.03 per share

Price / Book6.67

Profitability

EPS (Most Recent Fiscal Year)($2.09)

Net Income$-53,790,000.00

Net MarginsN/A

Return on Equity-28.65%

Return on Assets-26.12%

Miscellaneous

Employees65

Outstanding Shares33,040,000

Market Cap$2.21 billion

Next Earnings Date8/13/2020 (Estimated)

OptionableNot Optionable

Receive PRNB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRNB and its competitors with MarketBeat's FREE daily newsletter.

Principia Biopharma (NASDAQ:PRNB) Frequently Asked Questions

How has Principia Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Principia Biopharma's stock was trading at $53.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRNB shares have increased by 24.2% and is now trading at $66.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Principia Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Principia Biopharma.

When is Principia Biopharma's next earnings date?

Principia Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Principia Biopharma.

How were Principia Biopharma's earnings last quarter?

Principia Biopharma Inc (NASDAQ:PRNB) posted its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $0.20. View Principia Biopharma's earnings history.

What price target have analysts set for PRNB?

5 analysts have issued twelve-month price objectives for Principia Biopharma's shares. Their forecasts range from $76.00 to $82.00. On average, they anticipate Principia Biopharma's stock price to reach $78.60 in the next twelve months. This suggests a possible upside of 17.5% from the stock's current price. View analysts' price targets for Principia Biopharma.

Has Principia Biopharma been receiving favorable news coverage?

News headlines about PRNB stock have trended very positive on Thursday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Principia Biopharma earned a news impact score of 3.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutPrincipia Biopharma.

Who are some of Principia Biopharma's key competitors?

Some companies that are related to Principia Biopharma include Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), United Therapeutics (UTHR), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), Mirati Therapeutics (MRTX) and Emergent Biosolutions (EBS). View all competitors.

What other stocks do shareholders of Principia Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include AbbVie (ABBV), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Corbus Pharmaceuticals (CRBP) and Five Prime Therapeutics (FPRX).

Who are Principia Biopharma's key executives?

Principia Biopharma's management team includes the following people:

Dr. Alan B. Colowick Ph.D., M.D., M.P.H., Exec. Chairman (Age 57)
Mr. Martin Babler, CEO & Director (Age 54)
Mr. Christopher Y. Chai, Chief Financial Officer (Age 52)
Ms. Stefani A. Wolff, Chief Devel. Officer (Age 57)
Dr. David M. Goldstein, Chief Scientific Officer (Age 53)

When did Principia Biopharma IPO?

(PRNB) raised $75 million in an IPO on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

What is Principia Biopharma's stock symbol?

Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB."

Who are Principia Biopharma's major shareholders?

Principia Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Redmile Group LLC (6.84%), Cormorant Asset Management LP (6.36%), BlackRock Inc. (5.93%), Wellington Management Group LLP (4.87%), State Street Corp (1.98%) and Pictet Asset Management Ltd. (1.37%). Company insiders that own Principia Biopharma stock include Alan Colowick, Christopher Y Chai, Daniel J Becker, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Orbimed Advisors Llc, Plc Glaxosmithkline, Roy C Hardiman, Simeon George, Srinivas Akkaraju and Stefani Wolff. View institutional ownership trends for Principia Biopharma.

Which major investors are selling Principia Biopharma stock?

PRNB stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Redmile Group LLC, Nuveen Asset Management LLC, Pictet Asset Management Ltd., Massachusetts Financial Services Co. MA, JPMorgan Chase & Co., Alliancebernstein L.P., and AXA. Company insiders that have sold Principia Biopharma company stock in the last year include Alan Colowick, Christopher Y Chai, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Roy C Hardiman, and Stefani Wolff. View insider buying and selling activity for Principia Biopharma.

Which major investors are buying Principia Biopharma stock?

PRNB stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Cormorant Asset Management LP, BlackRock Inc., Aviva PLC, First Trust Advisors LP, State Street Corp, Grantham Mayo Van Otterloo & Co. LLC, and Two Sigma Investments LP. Company insiders that have bought Principia Biopharma stock in the last two years include Daniel J Becker, Leaf Ventures Ii LP New, Plc Glaxosmithkline, Simeon George, and Srinivas Akkaraju. View insider buying and selling activity for Principia Biopharma.

How do I buy shares of Principia Biopharma?

Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Principia Biopharma's stock price today?

One share of PRNB stock can currently be purchased for approximately $66.91.

How big of a company is Principia Biopharma?

Principia Biopharma has a market capitalization of $2.21 billion and generates $35.16 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Principia Biopharma employs 65 workers across the globe.

What is Principia Biopharma's official website?

The official website for Principia Biopharma is www.principiabio.com.

How can I contact Principia Biopharma?

Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff